SIGA Technologies, Inc. - 10-Q Summary (Period Ended September 30, 2008)
Business Context and Reporting Period
SIGA Technologies, Inc. is a bio-defense company focused on the discovery and development of products against biological warfare agents (e.g., smallpox, Arenaviruses) and novel anti-infectives. The company has no commercial products and relies on government grants, contracts, and financing to fund operations. This report covers the quarterly period ended September 30, 2008.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2008 |
|---|---|---|
| Revenues | $1,862,557 | $5,577,055 |
| Net Loss | $(3,028,881) | $(7,027,921) |
| Net Loss Per Share (Basic) | $(0.09) | $(0.20) |
| Cash and Cash Equivalents (End of Period) | $2,957,755 | |
| Net Cash Used in Operating Activities (9 Months) | $(6,396,105) | |
| Total Liabilities | $7,513,843 | |
| Stockholders' Equity | $2,283,666 |
Note: The company recorded a non-cash loss of $923,217 for the nine months ended September 30, 2008, due to the increase in the fair market value of common stock warrants classified as liabilities.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 13% year-over-year for the nine-month period ($5.58M vs. $4.94M), driven primarily by a $2.3M increase in NIH grants and contracts. Conversely, revenue from USAF programs dropped significantly as two one-year agreements were completed in 2008.
- Expense Increases: Operating expenses rose to $11.77M for the nine months ended September 30, 2008, compared to $10.33M in the prior year. Research and Development (R&D) expenses increased by $1.0M (14%) due to higher clinical and pre-clinical testing costs for lead drug candidates.
- Liquidity Decline: Cash and cash equivalents decreased by approximately $3.87M during the nine-month period, falling from $6.83M at year-end 2007 to $2.96M at September 30, 2008.
- Warrant Liability: The fair value of common stock warrants increased, resulting in a $923,217 loss for the nine-month period, compared to a $32,198 loss in the same period of 2007.
Guidance, Outlook, and Risks
- New Funding: In September 2008, SIGA was awarded a five-year, $55.0 million contract from the NIAID/NIH for the development of ST-246 (smallpox candidate). Additionally, a $20.0 million supplemental award was received to accelerate manufacturing and packaging validation.
- Financing Commitment: On June 19, 2008, the company entered into a letter agreement with MacAndrews & Forbes, LLC, committing up to $8 million in investment over one year.
- Liquidity Outlook: Management believes existing cash, combined with anticipated government grants and the investment commitment, will support operations beyond the next twelve months. However, the company expects to continue incurring operating losses and will require additional capital to complete product development.
- Legal Contingency: PharmAthene, Inc. has filed a lawsuit seeking a license agreement for SIGA-246 and damages for alleged breach of obligation. The court denied SIGA's motion to dismiss in January 2008, and discovery is proceeding. SIGA intends to defend itself vigorously.
- Risk Factors: Significant risks include the failure of clinical trials, inability to secure future financing, and the high cost and uncertainty of completing drug development programs.
Key Facts for Investor Verification
- Verify the status and terms of the $55M NIAID contract and the $20M supplemental award to ensure revenue recognition assumptions are met.
- Monitor the outcome of the PharmAthene, Inc. litigation, which could result in significant damages or forced licensing of the lead asset (ST-246).
- Assess the company's cash burn rate against the $2.96M cash balance to determine the runway before additional financing is required.
- Review the valuation methodology for the common stock warrants, as changes in fair value significantly impact reported net loss.
- Confirm the progress of ST-246 clinical trials, as the company estimates $20M-$30M in remaining costs to complete the program.